KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Treasury Shares (2016 - 2026)

Esperion Therapeutics filings provide 6 years of Treasury Shares readings, the most recent being $55.0 million for Q4 2025.

  • On a quarterly basis, Treasury Shares changed 0.0% to $55.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.0 million, a 0.0% change, with the full-year FY2025 number at $55.0 million, changed 0.0% from a year prior.
  • Treasury Shares hit $7.1 million in Q4 2025 for Esperion Therapeutics, up from $2.0 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $8.0 million in Q2 2025 to a low of $2.0 million in Q1 2021.
  • Median Treasury Shares over the past 5 years was $2.0 million (2021), compared with a mean of $3.3 million.
  • The widest YoY moves for Treasury Shares: up 0.0% in 2021, down 0.0% in 2021.
  • Esperion Therapeutics' Treasury Shares stood at $55.0 million in 2021, then changed by 0.0% to $55.0 million in 2022, then changed by 0.0% to $55.0 million in 2023, then changed by 0.0% to $55.0 million in 2024, then changed by 0.0% to $55.0 million in 2025.
  • The last three reported values for Treasury Shares were $55.0 million (Q4 2025), $55.0 million (Q3 2025), and $55.0 million (Q2 2025) per Business Quant data.